NCT02344940View on ClinicalTrials.gov

Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Breast Cancer
Interventions
DRUG

Toremifene

patients will take toremifene 60 mg qd.

DRUG

Tamoxifen

patients will take tamoxifen 10 mg bid.

Trial Locations (1)

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT02344940 - Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | Biotech Hunter | Biotech Hunter